Related Experiment Video
Updated: Feb 6, 2026

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
Published on: March 24, 2023
EXPERIMENTAL ASSESSMENT OF THE SPECIFIC EFFICIENCY OF NEW METABOLIC DRUG RUNIKHOL ON MODELS OF NON-ALCOHOLIC FATTY
Abstract:
We present results of preclinical evaluation of the specific efficiency of new metabolic corrector runikhol on models of non-alcoholic fatty liver disease in laboratory rats (228 albino males of gray Wistar rats weighing 220 - 240 g). The drug based on succinic acid positively influences the key types of metabolism impaired under conditions of development of the metabolic syndrome. Results of research testify to high efficiency and good prospects of using runikhol in the treatment of metabolic syndrome accompanied by organ disorders.
More Related Videos
09:27Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish
Published on: April 1, 2021
06:26Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
Related Concept Videos
Overview of Fatty Acid Metabolism
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cell Specific Gene Expression
Drug Metabolism: Phase I Reactions